ecc0509
Osteoarthritis
EccogenePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Osteoarthritis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Naltrexone Brigham and Women's Hospital | Phase 4 | BBB |
Buprenorphine Mundipharma Pte Ltd. | Phase 4 | BBB |
Oxycodone Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | BBB |
FENTANYL Janssen Pharmaceutica | Phase 4 | BBB |
Liraglutide Henrik Gudbergsen | Phase 4 | BBB |
View all 47 →
Same molecule, other indications
ecc0509 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →